Related Experiment Video
Updated: Dec 14, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.6K
Where to next prostate-specific membrane antigen PET imaging frontiers?
Maarten L Donswijk1, Joshua J Morigi2, Adrienne Little2
1Department of Nuclear Medicine.
Current Opinion in Urology
|July 24, 2020
Summary
Advancements in PET/CT imaging and PSMA ligands enhance urology and nuclear medicine synergy for prostate cancer. Artificial intelligence integration promises future breakthroughs in nuclear imaging applications.
Area of Science:
- Nuclear Medicine
- Urology
- Radiology
- Artificial Intelligence
Background:
- Synergy between Urology and Nuclear Medicine is increasing due to technical advancements in imaging equipment.
- The introduction of artificial intelligence (AI) is poised to revolutionize Nuclear Imaging.
- Prostate-Specific Membrane Antigen (PSMA) ligands are key radiotracers driving these developments.
Purpose of the Study:
- To provide an overview of recent technical and clinical developments in nuclear imaging.
- To explore the future applications of these advancements in urology and nuclear medicine.
- To highlight the impact of AI and novel radiotracers on prostate cancer imaging.
Main Methods:
- Review of recent technical improvements in PET/CT instrumentation, including digital and total-body PET/CT.
- Analysis of the clinical applications of PSMA-ligand PET imaging in prostate cancer management.
- Assessment of the emerging role and potential of artificial intelligence in nuclear imaging.
Main Results:
- Digital PET/CT shows improved lesion detection; total-body PET/CT offers enhanced scan quality, duration, and dose optimization.
- PSMA-ligand PET-guided decision-making is valuable for primary tumor biopsy, radiotherapy guidance, recurrent prostate cancer surgery, and therapy response assessment.
- Artificial intelligence is demonstrating significant promise for future clinical applications in nuclear imaging.
Conclusions:
- Growing evidence supports the clinical utility of PSMA-ligand PET imaging for prostate cancer management.
- Rapid advancements in PET instrumentation and AI integration are expected to transform nuclear imaging.
- Mastering and integrating these powerful new tools into clinical practice is crucial for future success.
Related Concept Videos
01:29Positron Emission Tomography
6.7K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.7K
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
377
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
377